MarketInOut Stock Screener Log In | Sign Up
 

HCW Biologics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/23/2026
HCW Biologics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2.5 mln
Float2.01 mln
Earnings Date11/12/2026

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

3.25
Highly suspicious

1-Year Forecast

48.00
Transformational upside

Relative Strength

8 / 100
Severely lagging

Debt / Equity

0.88
Moderate leverage

Pre-Tax Margin

-78%
Severely loss-making

Business Description

HCW Biologics is a US-based drug development company focused on creating new treatments for diseases linked to aging and long-term inflammation. Founded in 2018 and based in Miramar, Florida, the company is advancing several experimental medicines through clinical trials, including therapies targeting solid tumor cancers, autoimmune conditions, and other age-related illnesses. It also holds partnership agreements with Wugen Inc. and WY Biotech to expand the reach of its treatment pipeline through shared research and licensing arrangements.

Key Fundamentals

EPS-19.84
ROE-202
RPS8.53
ROIC-19.11
ROA-20.99
Interest Cover-17.08
EBITDA, mln-4.10
EV / EBITDA-2.00
EV / EBIT-1.74
Revenue, mln6.72
EV / Revenue1.22

Quote Details

Last 1.17
Change 0.05 (4.46%)
Open 1.12
Volume 77,087
Turnover 90,192
Average Volume 176,493

Financial Ratios

Pre-Tax Profit Margin-78
Leverage Ratio3.60
Current Ratio0.06
Price / Book0.37
Price / Tangible Book0.37
Debt / Equity0.88
Price / Sales0.24

Financial Strength

Altman Z-Score-6.76
Piotroski F-Score 4 / 9
Beneish M-Score3.25
1-Year Target Price48.00
Short Ratio0.07
Short % of Float2.85

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -5.65% 15 / 100   
1 Month -41.21% 7 / 100   
2 Months -69.45% 4 / 100   
6 Months -48% 13 / 100   
1 Year -95.03% 3 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Blog